A Review on Treatments of Gout for Future Aspects

Authors

  • Manpreet Singh
  • Madan L. Kaushik

DOI:

https://doi.org/10.37591/(rrjops).v8i3.4

Abstract

Gout is the most common inflammatory arthritis in adults, and is caused by excess uric acid pools in the body, which leads to the formation of monosodium urate (MSU) crystals and their deposition in and around joints where they induce inflammation, leading to acute gout attacks. The extreme inflammatory burden and pain of an acute gout attack can be unbearable. The prevalence of gout appears to be increasing and may affect up to 8 million people in the United States and this disease mainly occurs in men aged more than 50, affecting approximately 1–2% of adult men in the western world. The development of novel therapies for gout after 40 years has opened new understanding of this disease. A study from Vellore revealed that 15.8% of the affected patients are less than 30 years. The quality of care for many patients with gout is unfortunately not in keeping with current guidelines. Rather than providing a comprehensive overview of gout, this review focuses on various classes of drugs used in the treatment of gout such as short-term and long treatments with allopathic medicines and alternative medicines.

Keywords: Gout, monosodium urate crystals, allopathic medicines, alternative medicines

Cite this Article Manpreet Singh, Kaushik Madan L. A Review on Treatments of Gout for Future Aspects. Research and Reviews: A Journal of Pharmaceutical Science. 2017; 8(3):    1–6p. 

Downloads

Published

2017-12-04

Issue

Vol. 8 No. 3 (2017)

Section

Research Article

License

Declaration and Copyright Transfer Form

(to be completed by authors)

I/ We, the undersigned author(s) of the submitted manuscript, hereby declare, that the above manuscript which is submitted for publication in the STM Journals(s), is not published already in part or whole (except in the form of abstract) in any journal or magazine for private or public circulation, and, is not under consideration of publication elsewhere.

  • I/We will not withdraw the manuscript after 1 week of submission as I have read the Author Guidelines and will adhere to the guidelines.
  • I/We Author(s ) have niether given nor will give this manuscript elsewhere for publishing after submitting in STM Journal(s).
  • I/ We have read the original version of the manuscript and am/ are responsible for the thought contents embodied in it. The work dealt in the manuscript is my/ our own, and my/ our individual contribution to this work is significant enough to qualify for authorship.
  •  I/We also agree to the authorship of the article in the following order:

Author’s name                                    

 

1. ________________

2. ________________

3. ________________

4. ________________

 

We  Author(s) tick this box and would request you to consider it as our signature as we agree to the terms of this Copyright Notice, which will apply to this submission if and when it is published by this journal.